• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病患者脑脊液中高分子量β-淀粉样寡聚物升高。

High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.

机构信息

Pharmacology Research Division, Takeda Pharmaceutical Company, Osaka, Japan.

出版信息

FASEB J. 2010 Aug;24(8):2716-26. doi: 10.1096/fj.09-150359. Epub 2010 Mar 25.

DOI:10.1096/fj.09-150359
PMID:20339023
Abstract

There is accumulating evidence that soluble amyloid-beta (Abeta) oligomers, rather than amyloid fibrils, are the principal pathogenic species in Alzheimer disease (AD). Here, we have developed a novel enzyme-linked immunosorbent assay (ELISA) specific for high-molecular-weight (HMW) Abeta oligomers. Analysis of Abeta oligomers derived from synthetic Abeta 1-42, by size-exclusion chromatography (SEC), revealed that our ELISA specifically detected HMW Abeta oligomers of 40-200 kDa. Using this ELISA, we detected significantly higher (P<0.0001) signals in cerebrospinal fluid (CSF) samples from 25 patients with AD or mild cognitive impairment (MCI), compared to 25 age-matched controls. As a test for discriminating between the AD/MCI and control groups, the area under the curve in receiver operating characteristic analysis for the CSF HMW Abeta oligomers was greater than that for CSF Abeta x-42. Furthermore, the CSF levels of HMW Abeta oligomers showed a negative correlation with Mini-Mental State Examination scores in the AD/MCI group. We conclude that the CSF HMW Abeta oligomers detected by our ELISA could be useful as a diagnostic marker for AD, and also as a potential surrogate marker for disease severity. Our results support the idea that soluble HMW Abeta oligomers play a critical role in the pathogenesis and progression of AD.

摘要

越来越多的证据表明,可溶性淀粉样β(Abeta)寡聚体而不是淀粉样纤维是阿尔茨海默病(AD)的主要致病物质。在这里,我们开发了一种针对高分子量(HMW)Abeta 寡聚体的新型酶联免疫吸附测定(ELISA)。通过尺寸排阻色谱(SEC)对合成 Abeta 1-42 衍生的 Abeta 寡聚体进行分析,结果表明我们的 ELISA 特异性检测到 40-200 kDa 的 HMW Abeta 寡聚体。使用该 ELISA,我们在来自 25 名 AD 或轻度认知障碍(MCI)患者的脑脊液(CSF)样本中检测到明显更高的(P<0.0001)信号,与 25 名年龄匹配的对照组相比。作为区分 AD/MCI 和对照组的测试,CSF HMW Abeta 寡聚体的接收器操作特性分析中的曲线下面积大于 CSF Abeta x-42。此外,AD/MCI 组中 CSF HMW Abeta 寡聚体水平与 Mini-Mental State Examination 评分呈负相关。我们得出结论,我们的 ELISA 检测到的 CSF HMW Abeta 寡聚体可用作 AD 的诊断标志物,也可用作疾病严重程度的潜在替代标志物。我们的结果支持可溶性 HMW Abeta 寡聚体在 AD 的发病机制和进展中起关键作用的观点。

相似文献

1
High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.阿尔茨海默病患者脑脊液中高分子量β-淀粉样寡聚物升高。
FASEB J. 2010 Aug;24(8):2716-26. doi: 10.1096/fj.09-150359. Epub 2010 Mar 25.
2
Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.脑脊髓液中的淀粉样β寡聚体与阿尔茨海默病患者的认知能力下降有关。
J Alzheimers Dis. 2012;29(1):171-6. doi: 10.3233/JAD-2012-111361.
3
The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease.脑脊液中淀粉样β寡聚体的计数是阿尔茨海默病的生物标志物。
J Alzheimers Dis. 2013;34(4):985-94. doi: 10.3233/JAD-122047.
4
Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.脑脊液中异常磷酸化的tau蛋白和β淀粉样蛋白片段与轻度认知障碍(MCI)受试者的认知障碍相关。
Neurobiol Aging. 2006 Feb;27(2):237-44. doi: 10.1016/j.neurobiolaging.2005.01.011. Epub 2005 Apr 7.
5
The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.阿尔茨海默病患者脑脊液中的淀粉样β寡聚物负荷降低。
J Alzheimers Dis. 2012;31(4):865-78. doi: 10.3233/JAD-2012-120211.
6
Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.阿尔茨海默病的脑脊液生物标志物:在同质单中心人群中的诊断性能。
J Alzheimers Dis. 2011;24(3):537-46. doi: 10.3233/JAD-2011-101878.
7
CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.脑脊液可溶性淀粉样前体蛋白在早期阿尔茨海默病诊断中的应用。
Neurology. 2011 Jul 5;77(1):35-8. doi: 10.1212/WNL.0b013e318221ad47. Epub 2011 Jun 22.
8
CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.脑脊髓液中心脏脂肪酸结合蛋白水平在阿尔茨海默病早期发生改变。
J Alzheimers Dis. 2010;22(4):1281-8. doi: 10.3233/JAD-2010-101293.
9
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.脑脊液β-淀粉样蛋白1-42和tau蛋白作为轻度认知障碍患者阿尔茨海默病预测指标的价值
Mol Psychiatry. 2004 Jul;9(7):705-10. doi: 10.1038/sj.mp.4001473.
10
Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.通过 ELISA 在脑脊液和脑组织中检测淀粉样蛋白-β寡聚物。
Anal Biochem. 2013 Feb 15;433(2):112-20. doi: 10.1016/j.ab.2012.09.014. Epub 2012 Sep 26.

引用本文的文献

1
Altered protein homeostasis in cardiovascular diseases contributes to Alzheimer's-like neuropathology.心血管疾病中蛋白质稳态的改变会导致阿尔茨海默病样神经病理学变化。
Basic Res Cardiol. 2025 May 7. doi: 10.1007/s00395-025-01109-w.
2
Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls.联合检测Aβ40、Aβ42和血浆 Tau 水平以区分淀粉样蛋白PET阳性的阿尔茨海默病患者与正常对照。
Exp Neurobiol. 2025 Feb 28;34(1):1-8. doi: 10.5607/en25008.
3
Plasma amyloid-β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort.
血浆淀粉样β寡聚化倾向作为轻度认知障碍转化为阿尔茨海默病痴呆的潜在预测指标:来自GMCII队列的研究结果
Alzheimers Dement (Amst). 2025 Feb 24;17(1):e70064. doi: 10.1002/dad2.70064. eCollection 2025 Jan-Mar.
4
High-molecular-weight oligomer tau (HMWoTau) species are dramatically increased in Braak-stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer Tau ELISA with a mouse monoclonal antibody (APNmAb005).高分子量寡聚体 tau(HMWoTau)物种在人类大脑额叶中以明显的 Braak 阶段依赖性方式增加,这是通过一种新型的寡聚 Tau ELISA 与小鼠单克隆抗体(APNmAb005)来证明的。
FASEB J. 2024 Nov 30;38(22):e70160. doi: 10.1096/fj.202401704R.
5
Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.阿尔茨海默病患者粪便中升高的 Aβ 聚集物:概念验证研究。
Alzheimers Res Ther. 2024 Oct 14;16(1):223. doi: 10.1186/s13195-024-01597-3.
6
New BDNF and NT-3 Cyclic Mimetics Concur with Copper to Activate Trophic Signaling Pathways as Potential Molecular Entities to Protect Old Brains from Neurodegeneration.新型 BDNF 和 NT-3 环状模拟物与铜协同激活营养信号通路,作为保护老年大脑免受神经退行性变的潜在分子实体。
Biomolecules. 2024 Sep 2;14(9):1104. doi: 10.3390/biom14091104.
7
"Prion-like" seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders.神经退行性疾病中寡聚蛋白聚集体的“类朊病毒”种子形成与传播
Front Neurosci. 2024 Aug 5;18:1436262. doi: 10.3389/fnins.2024.1436262. eCollection 2024.
8
Intracerebral inoculation of healthy non-transgenic rats with a single aliquot of oligomeric amyloid-β (1-42) profoundly and progressively alters brain function throughout life.用单一等分试样的寡聚淀粉样蛋白β(1-42)对健康的非转基因大鼠进行脑内接种,会在其一生中深刻且渐进地改变脑功能。
Front Aging Neurosci. 2024 Aug 2;16:1397901. doi: 10.3389/fnagi.2024.1397901. eCollection 2024.
9
Targeting soluble amyloid-beta oligomers with a novel nanobody.靶向可溶性淀粉样β寡聚体的新型纳米抗体。
Sci Rep. 2024 Jul 12;14(1):16086. doi: 10.1038/s41598-024-66970-6.
10
GluN2A or GluN2B subunits of the NMDA receptor contribute to changes in neuronal excitability and impairments in LTP in the hippocampus of aging mice but do not mediate detrimental effects of oligomeric Aβ (1-42).N-甲基-D-天冬氨酸受体(NMDA受体)的GluN2A或GluN2B亚基会导致衰老小鼠海马体中神经元兴奋性的变化以及长时程增强(LTP)受损,但不会介导低聚β淀粉样蛋白(1-42)的有害作用。
Front Aging Neurosci. 2024 May 20;16:1377085. doi: 10.3389/fnagi.2024.1377085. eCollection 2024.